Updates Clinical

Total Page:16

File Type:pdf, Size:1020Kb

Updates Clinical Clinical ® PAIN Updates INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN® Volume XIII, No.2 June 2005 EDITORIAL BOARD Editor-in-Chief Daniel B. Carr, MD The Challenge of Preemptive Analgesia Internal Medicine, Endocrinology, Anesthesiology USA Advisory Board 1 Elon Eisenberg, MD n 1988, Wall reviewed emerging data showing that analgesia before surgical Neurology I incision or amputation decreased postsurgical pain or reduced the incidence of Israel phantom pain, respectively, and decreased the amount of postoperative analgesic James R. Fricton, DDS, MS Dentistry, Orofacial Pain needed. Wall’s publication may be the first review of “preemptive analgesia,” USA which is defined as intervention preceding surgery for the purpose of preventing Maria Adele Giamberardino, MD or decreasing postsurgical pain by preventing central sensitization. To attain Internal Medicine, Physiology Italy preemptive analgesia, however, several critical principles must be applied suc- Cynthia R. Goh, MB BS, FRCP, PhD cessfully. Failure to apply all of these principles may lead to inadequate postsur- Palliative Medicine Singapore gical analgesia. In addition, in patients with pre-existing pain before surgery, Alejandro R. Jadad, MD, PhD preemptive analgesia is unfeasible because central sensitization has already oc- Anesthesiology, Evidence-Based curred due to presurgical pain. This issue of Pain: Clinical Updates surveys the Medicine and Consumer Issues Canada basis for, and challenges facing, preemptive analgesia and presents a practical Andrzej W. Lipkowski, PhD, DSc method for its successful practice. Neuropharmacology and Peptide Chemistry Poland Central Sensitization and Wind-up Patricia A. McGrath, PhD Psychology, Pediatric Pain Canada In response to nociceptive impulses, c-fos, a gene expressed rapidly in many Mohammad Sharify, MD types of cells in response to various stimuli, is expressed in spinal dorsal horn Family Medicine, Rheumatology and supraspinal neurons. In these and other cells along nociceptive pathways, Iran c-fos expression serves as a marker for cellular activation, i.e., nociception. C-fos Bengt H. Sjolund, MD, PhD Neurosurgery, Rehabilitation expression is followed by central sensitization—a lowering of the threshold for Sweden responses to further stimuli and hyperalgesia.2,3 In addition, electrophysiological Maree T. Smith, PhD Pharmacology experiments have shown that repetitive low-frequency stimulation of C fibers Australia (0.5–2 Hz) lowers the threshold for activation of spinal cord neurons and pro- Harriët M. Wittink, PhD, PT longs their discharge following brief stimuli (wind-up).2,3Both central sensitiza- Physical Therapy The Netherlands tion and wind-up intensify pain perception, and both depend on activation of N-methyl-D-aspartate (NMDA) receptors.2,3 In other words, pain memories im- Production Elizabeth Endres, Copy Editing printed within the central nervous system by NMDA-receptor activation produce Kathleen E. Havers, Executive Assistant 4 Juana Braganza Peck, Layout/Graphics hyperalgesia and contribute to symptoms such as allodynia. Therefore, postsur- gical pain may in theory be preventable by presurgical nociceptive blockade with epidural anesthesia and an epidural opioid (anesthesia/analgesia). In animal experiments, c-fos expression, central sensitization, and wind-up do not occur if UPCOMING ISSUES nociceptive blockade is applied prior to the nociceptive event.2,3 These findings suggest that presurgical blockade of nociception may prevent postsurgical wound Visceral Pain pain or pain hypersensitivity in clinical surgery, thus providing preemptive anal- Genetic Influences gesia as advocated by Wall.1 Indeed, within a decade of the introduction of local Pain and Aging anesthetic techniques for regional analgesia, a similar hypothesis had been advanced by Crile.5 Supported by an educational grant from Endo Pharmaceuticals Inc., USA Three Critical Principles Postsurgical Central Sensitization Achieving successful preemptive analgesia is challenging. Many postsurgical stimuli, including movement and wound Central sensitization is easily initiated even by trifling nocicep- care of the surgical incision, can establish central sensitization tive impulses6 that can occur when an anesthesiologist neglects by themselves. Especially after open-chest surgery, repeated analgesia during surgery—even if briefly or to a small degree. respiratory efforts and intermittent abrupt movements such as In that case, preemptive analgesia will fail. To attain successful coughing or sneezing stimulate the skin, muscles, pleura, lungs, preemptive analgesia, “complete analgesia” must be (1) deep and mediastinum. These movements can easily trigger postsur- enough to block all nociception, (2) wide enough to cover the gical central sensitization. Furthermore, intercostal nerves are entire surgical area, and (3) prolonged enough to last throughout sometimes injured during surgery, commonly leading to inter- surgery and even into the postoperative period. When careless- costal causalgia (complex regional pain syndrome, type II).9 ness results in failure to achieve all three critical principles, Therefore, meticulous postsurgical analgesia can be a crucial preemptive analgesia is likely to fail. component of perioperative preemptive analgesia. Clearly, ef- fective treatment must protect patients from postsurgical pain. Presurgical Pain Overcomes Preemptive Analgesia Multiple Nerve Innervations When patients have pre-existing pain well in advance of surgery, presurgical analgesic interventions in the immediate Surgical sites in the abdomen and chest have redundant presurgical period cannot have a postsurgical analgesic effect. innervation via somatic and autonomic nerves. Both pathways In such cases, presurgical intervention does not yield preemp- transmit nociceptive signals to the thalamus. Somatic nerves tive analgesia because central sensitization has already begun (except for the phrenic nerve), sympathetic nerves, and sacral long before surgery.7 In operations for trauma such as bone parasympathetic nerves enter the spine at thoracic levels or fractures or during inflammatory states such as appendicitis, lower, whereas the phrenic and vagus nerves enter the cervical peritonitis, and osteoarthritis, residual inflammation after sur- spine and brainstem, respectively. The phrenic nerve generally gery produces lingering pain and ongoing central sensitization.8 controls motor and sensory function of the diaphragm. In addi- In the above circumstances, any interventions just before tion, sensations from the trachea, bronchi, pericardium, pleura, surgery are already too late; analgesia throughout surgery, esophagus, esophagocardial junction, and subphrenic perito- “postemptive analgesia,” is limited to maintaining the presur- neum are also conveyed via the phrenic nerve. Although the gical sensitization level. With inadequate operative analgesia, phrenic innervation is segmental in the early embryo, it devel- intrasurgical nociceptive impact builds upon the presurgically ops broader visceral projections during later development. initiated sensitization, and the magnitude of sensitization is Consequently, heterosegmental innervations are formed. In reset even higher.7 open-chest surgery or subphrenic abdominal surgery, the Table 1. Single and multiple innervations of common somatic and visceral surgical sites Innervation Organs Segmental Heterosegmental Head, face Cranial nerves Neck, nape Cervical nerves Body surface Spinal nerve Extremities Spinal nerve Chest Esophagus Thoracic nerve Phrenic nerve Vagus nerve Trachea, bronchus Thoracic nerve Phrenic nerve Vagus nerve Lung Thoracic nerve Phrenic nerve Vagus nerve Pleura Thoracic nerve Phrenic nerve Vagus nerve Heart Thoracic nerve Vagus nerve Pericardium Thoracic nerve Phrenic nerve Vagus nerve Diaphragm Thoracic nerve Phrenic nerve Vagus nerve Abdomen Subphrenic peritoneum Thoracic nerve Phrenic nerve Vagus nerve Esophagocardial junction Thoracic nerve Phrenic nerve Vagus nerve Abdominal organs Thoracic nerve Vagus nerve Peritoneum Thoracic nerve Vagus nerve Mesenterium Thoracic nerve Vagus nerve Retroperitoneal organs Thoracic nerve Vagus nerve Urogenital organs Lumbosacral nerve Vagus nerve 2 surgical area receives three-fold innervation from the spinal, vagus, and/or phrenic nerves (Table 1). Total regional anesthe- sia/analgesia covering the surgical area cannot be achieved with routine spinal or epidural analgesia, nor do such techniques ablate the stress hormone response to these operations.10 Thus, supplemental analgesia is required to silence the vagus and phrenic nerves in preemptive analgesia with regional anesthe- sia/analgesia. Animal Experiments Those who question the utility of preemptive analgesia often state that the technique is reliable in animal experiments but has variable results in clinical studies. The disparity between animal and clinical study results can be explained by important differences in study design. First, experimental animals typically have no pre-existing Fig. 1. Primary nociceptive transmission in the spinal cord. Primary pain, whereas many surgical patients present with presurgical afferent nociceptive input is transmitted via AMPA, neurokinin-1 pain. Second, in experimental animals, the stimulus is typically (NK1), and calcitonin gene-related peptide (CGRP) synapses, whose applied to the extremities or the tail, which are only segmentally signals work their way to the thalamus. Glutaminergic (NMDA) synapses do not participate significantly in primary
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0024006 A1 Simon (43) Pub
    US 2004.0024006A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0024006 A1 Simon (43) Pub. Date: Feb. 5, 2004 (54) OPIOID PHARMACEUTICAL May 30, 1997, now abandoned, and which is a COMPOSITIONS continuation-in-part of application No. 08/643,775, filed on May 6, 1996, now abandoned. (76) Inventor: David Lew Simon, Mansfield Center, CT (US) Publication Classification Correspondence Address: (51) Int. Cl. ................................................ A61K 31/485 David L. Simon (52) U.S. Cl. .............................................................. 514/282 P.O. Box 618 100 Cemetery Road (57) ABSTRACT Mansfield Center, CT 06250 (US) The invention is directed in part to dosage forms comprising a combination of an analgesically effective amount of an (21) Appl. No.: 10/628,089 opioid agonist analgesic and a neutral receptor binding agent or a partial mu-opioid agonist, the neutral receptor binding (22) Filed: Jul. 25, 2003 agent or partial mu-opioid agonist being included in a ratio Related U.S. Application Data to the opioid agonist analgesic to provide a combination product which is analgesically effective when the combina (63) Continuation-in-part of application No. 10/306,657, tion is administered as prescribed, but which is leSS analge filed on Nov. 27, 2002, which is a continuation-in-part Sically effective or less rewarding when administered in of application No. 09/922,873, filed on Aug. 6, 2001, excess of prescription. Preferably, the combination product now Pat. No. 6,569,866, which is a continuation-in affects an opioid dependent individual differently from an part of application No. 09/152,834, filed on Sep.
    [Show full text]
  • Bispectral Index Monitoring Prevent Awareness During Total Intravenous Anesthesia: a Prospective, Randomized, Double-Blinded, Multi-Center Controlled Trial
    Awareness under TIVA Joseph Eldor, MD Chin Med J (Engl). 2011 Nov;124(22):3664-9. Bispectral index monitoring prevent awareness during total intravenous anesthesia: a prospective, randomized, double-blinded, multi-center controlled trial. Zhang C, Xu L, Ma YQ, Sun YX, Li YH, Zhang L, Feng CS, Luo B, Zhao ZL, Guo JR, Jin YJ, Wu G, Yuan W,Yuan ZG, Yue Y. Source Department of Anesthesiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China. Abstract BACKGROUND: Awareness is a serious complication of general anesthesia. In China, the incidence of intraoperative awareness was 1% in patients undergoing total intravenous anesthesia (TIVA). In this study, we compared the incidence of awareness between Bispectral index (BIS)- guided and routine TIVA protocol and evaluated the effect of BIS on preventing awareness. METHODS: A prospective, randomized, double-blinded, multicenter controlled trial was performed. Patients (≥ 18 years of age) undergoing TIVA were randomly divided into BIS-guided group (Group A, BIS was monitored and recommended to maintain between 40 - 60) and control group (Group B, BIS was monitored but the screen was covered). The intraoperative BIS values were downloaded and the BIS trends of confirmed awareness cases were analyzed to determine whether light anesthesia existed. RESULTS: Of the total 5228 patients, 2919 patients were assigned to Group A and 2309 to Group B. Four cases of confirmed awareness (0.14%) were reported in the BIS-guided group and 15 (0.65%) in the control group (P = 0.002, OR = 0.21, 95% confidence intervals: 0.07 - 0.63). The incidence of possible awareness (0.14% vs.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Types of Opioid Harms in Canadian Hospitals: Comparing Canada And
    Types of Opioid Harms in Canadian Hospitals: Comparing Canada and Australia Production of this document is made possible by financial contributions from Health Canada and provincial and territorial governments. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government. Unless otherwise indicated, this product uses data provided by Canada’s provinces and territories. All rights reserved. The contents of this publication may be reproduced unaltered, in whole or in part and by any means, solely for non-commercial purposes, provided that the Canadian Institute for Health Information is properly and fully acknowledged as the copyright owner. Any reproduction or use of this publication or its contents for any commercial purpose requires the prior written authorization of the Canadian Institute for Health Information. Reproduction or use that suggests endorsement by, or affiliation with, the Canadian Institute for Health Information is prohibited. For permission or information, please contact CIHI: Canadian Institute for Health Information 495 Richmond Road, Suite 600 Ottawa, Ontario K2A 4H6 Phone: 613-241-7860 Fax: 613-241-8120 www.cihi.ca [email protected] ISBN 978-1-77109-743-7 (PDF) © 2018 Canadian Institute for Health Information How to cite this document: Canadian Institute for Health Information. Types of Opioid Harms in Canadian Hospitals: Comparing Canada and Australia. Ottawa, ON: CIHI; 2018. Cette publication est aussi disponible en français sous le titre Types de
    [Show full text]
  • Disposal Systems of Transdermal Delivery Devices to Prevent Misuse of the Active Agents Contained Therein
    (19) & (11) EP 1 837 023 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.09.2007 Bulletin 2007/39 A61K 31/485 (2006.01) A61K 9/70 (2006.01) A61K 31/445 (2006.01) B09B 3/00 (2006.01) (2006.01) (21) Application number: 07003694.2 A61F 13/00 (22) Date of filing: 10.06.2003 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • Baker, Carl J. HU IE IT LI LU MC NL PT RO SE SI SK TR Middletown, NY 10941-5004 (US) Designated Extension States: • Shevchuck, Ihor AL LT LV MK Yonkers, NY 10710 (US) (30) Priority: 10.06.2002 US 387800 P (74) Representative: Maiwald Patentanwalts GmbH Elisenhof, (62) Document number(s) of the earlier application(s) in Elisenstrasse 3 accordance with Art. 76 EPC: 80335 München (DE) 03757468.8 / 1 513 532 Remarks: (71) Applicant: EURO-CELTIQUE S.A. This application was filed on 22 - 02 - 2007 as a 2330 Luxembourg (LU) divisional application to the application mentioned under INID code 62. (54) Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein (57) The present invention relates to a transdermal at least one deactivating agent to chemically alter, to de- delivery device disposal system for disposing of a grade, and/or to deactivate the active component (s) con- transdermal delivery device containing at least one phar- tained in the transdermal delivery device, such as an opi- maceutically active component. The disposal system oid antagonist or an opioid agonist deactivating agent so contains
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Percutaneously Absorbable Composition of Narcotic and Nonnarcotic Analgesics
    Europaisches Patentamt J European Patent Office © Publication number: 0 480 054 A1 Office europeen des brevets © EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC © Application number: 91906584.7 © Int. CI.5: A61K 45/08, A61 K 31/485, A61K 9/08, A61K 47/10, © Date of filing: 29.03.91 A61 K 47/46) A61 K 31 /55 © International application number: PCT/JP91/00413 © International publication number: WO 91/15241 (17.10.91 91/24) ® Priority: 30.03.90 JP 81180/90 © Applicant: Morimoto, Yasunori 7-22, Nishisakado 4-chome © Date of publication of application: Sakado-shi, Saitama-ken 350-02(JP) 15.04.92 Bulletin 92/16 © Inventor: MORIMOTO, Yasunori, 7-22, ® Designated Contracting States: Nishisakado 4-chome AT BE CH DE DK ES FR GB IT LI LU NL SE Sakado-shi Saitama-ken 350-02(JP) Inventor: SUGIBAYASHI, Kenji, 9-22, Nishisakado 4-chome Sakado-shi Saitama-ken 350-02(JP) Inventor: KOBAYASHI, Kouji, Toko Yakuhin Kogyo Kabushikikaisha 8-19, Shinden 3-chome Adachi-ku Tokyo 123(JP) Inventor: KUSANO, Hisashi, 19-304, Nishiageo No. 2 Danchi 2, 77-1 Oaza Koshikidani Ageo-shi Saitama-ken 362(JP) © Representative: Pearce, Anthony Richmond MARKS & CLERK Alpha Tower Suffolk Street Queensway Birmingham B1 1TT(GB) !£> © PERCUTANEOUSLY ABSORBABLE COMPOSITION OF NARCOTIC AND NONNARCOTIC ANALGESICS. o 00 © A percutaneously absorbable preparation comprising a narcotic analgesic of a low percutaneous absor- bability such as morphine hydrochloride or sulfate, a nonnarcotic analgesic such as eptazocine hydrobromide, a © percutaneous absorption promoter, and a percutaneous absorption promoter aid. Q_ UJ Rank Xerox (UK) Business Services EP 0 480 054 A1 Fig.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Thesis Introduction
    RESEARCH BACKGROUND: 1.1 HISTORY: Opioids have been used for centuries to produce euphoria, analgesia and sedation and prevent diarrhoea [Rang et al., 2003]. Opium extracted from the poppy plant, Papaver somniferum, was the first opioid isolated and used for medicinal purposes [Gutstein & Akil, 2001; Rang et al., 2003]. Assyrian medical references from 7000 B.C. refer to the use of this poppy juice while the Sumerians record usage from about 4000 B.C.. Egyptian papyri dating from 2000 B.C. report the use of opium for veterinary and gynaecological procedures and the use of the poppy is thought to have spread from here through Asia Minor and Greece. The use of this medicine then travelled with Arab traders through Persia, India and China and by the 10th and 11th centuries A.D., the opium trade was firmly established in Europe [Berridge & Edwards, 1981]. As availability increased, opium use became common and salves or elixirs containing opium were used as a sedative and anaesthetic throughout Europe in the 16th century. Even at this early time the potential for opium to cause “deepe deadly sleapes” was well known, as described by W.D. Bullein in his book “Bulwarke of defense against all sicknesse, soarnesse and woundes“ published in 1579 [Bullein, 1579]. The effectiveness of this compound, however, ensured its continued use. Over the following centuries, medicinal and recreational use continued, and despite the identification of the potential for opioid abuse and addiction, it was not openly discussed in the 1700s. While complications were known, opium was still readily available through grocer or druggist stores in England during the 1800s in the form of laudanum or tinctures, which are 1 Research Background: mixtures of opium, alcohol and various other ingredients.
    [Show full text]
  • List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify
    List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify, abnormal basal ganglia function, abuse of medicines, Aceperone, Acepromazine, Aceprometazine, Acetildenafil, Aceto phenazine, Acetoxy Dipt, Acetyl morphone, Acetyl propionyl morphine, Acetyl psilocin, Activation syndrome, acute anxiety, acute hypertension, acute panic attacks, Adderall, Addictions to drugs, Addictions to medicines, Addictions to substances, Adrenorphin, Adverse effects of psychoactive drugs, adverse reactions to medicines, aggression, aggressive, aggressiveness, agitated depression, Agitation and restlessness, Aildenafil, Akuammine, alcohol abuse, alcohol addiction, alcohol withdrawl, alcohol-related brain damage, alcohol- related liver damage, alcohol mix with medicines for adverse reaction, Alcoholism, Alfetamine, Alimemazine, Alizapride, Alkyl nitrites, allergic breathing reactions to meds, choking to anaphallectic shock, & death; allergic skin reactions to meds, rash, itchyness, hives, welts, etc, Alletorphine, Almorexant, Alnespirone, Alpha Ethyltryptamine, Alpha Neoendorphin, alterations in brain hormones, alterations in mental status, altered consciousness, altered mind, Altoqualine, Alvimopan, Ambien, Amidephrine, Amidorphin, Amiflamine, Amisulpride, Amphetamines, Amyl nitrite, Anafranil, Analeptic, Anastrozole, Anazocine, Anilopam, Antabuse, anti anxiety meds, anti dopaminergic activity, anti seizure meds, Anti convulsants, Anti depressants, Anti emetics, Anti histamines, anti manic meds, anti parkinsonics, Anti psychotics, Anxiety disorders,
    [Show full text]
  • FDA Briefing Document Joint Meeting of the Drug Safety and Risk Management (Dsarm) Advisory Committee and Anesthetic and Analges
    FDA Briefing Document Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) June 11-12, 2019 1 The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the advisory committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We have brought the clinical utility and safety concerns associated with the higher range of opioid analgesic dosing (both in terms of higher strength products and higher daily doses) in the outpatient setting, to this Advisory Committee in order to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered and all reviews have been finalized. The final determination may be affected by issues not discussed at the advisory committee meeting. 2 Table of Contents Page Office Director Memorandum 4 Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) Memorandum: Opioids Regulatory Background 9 Division of Epidemiology (DEPI) Review: Prescribing Patterns, Clinical Use, and Risks Associated with Higher Dosage Strength Products and Higher Daily Dosing of Opioid Analgesics 29 3 OFFICE DIRECTOR MEMORANDUM Department of Health and Human Services Public Health Service Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of Surveillance and Epidemiology (OSE) Date: May 22, 2019 From: Judy Staffa, Ph.D., R.Ph.
    [Show full text]
  • X-Ray Microscope Röntgenstrahlmikroskop Microscope À Rayons X
    (19) TZZ ___T (11) EP 2 511 844 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G06F 21/00 (2013.01) G21K 7/00 (2006.01) 12.08.2015 Bulletin 2015/33 (21) Application number: 12164870.3 (22) Date of filing: 10.10.2007 (54) X-ray microscope Röntgenstrahlmikroskop Microscope à rayons X (84) Designated Contracting States: • Stewart, Jeffrey, J. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Los Alamos, NM 87544 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Harris, Michael, N. SI SK TR Los Alamos, NM 87544 (US) • Burrell, Anthony, K. (30) Priority: 10.10.2006 US 850594 P Los Alamos, NM 87544 (US) (43) Date of publication of application: (74) Representative: Lorente Berges, Ana 17.10.2012 Bulletin 2012/42 A2 Estudio Legal C/ Hermosilla Nº 59, bajo izq (62) Document number(s) of the earlier application(s) in 28001 Madrid (ES) accordance with Art. 76 EPC: 07874491.9 / 2 084 519 (56) References cited: WO-A1-97/25614 US-A1- 2003 023 562 (73) Proprietor: XRpro Sciences, Inc. US-A1- 2004 128 518 US-A1- 2004 235 059 Los Alamos, NM 87544 (US) US-A1- 2005 015 596 (72) Inventors: • POTTS PHILIP J ET AL: "Atomic spectrometry • Birnbaum, Eva, R. update__X-ray fluorescence spectrometry", Los Alamos, NM 87544 (US) JOURNAL OF ANALYTICAL ATOMIC • Koppisch, Andrew, T. SPECTROMETRY, ROYAL SOCIETY OF Los Alamos, NM 87544 (US) CHEMISTRY, vol. 21, no.
    [Show full text]